Nasdaq:LENZ
LENZ Therapeutics, Inc.
A clinical-stage biotech firm leveraging proprietary small molecules to address severe pain and addiction markets.
Key Metrics
Investment Thesis
Bull Case
Investors may buy LENZ based on the high potential upside of its lead asset LNT-159 in the lucrative severe pain market; The company's strategic financing raises provide sufficient capital to advance clinical programs without immediate profitability pressure; Proprietary IP positions it as a leader in addressing the global opioid crisis.
Bear Case
The stock carries extreme risk due to zero revenue and accumulated retained earnings deficit of $145.0M indicating persistent burn rate; Significant cash outflows for investing activities of $154.5M suggest heavy capital requirements that could deplete reserves quickly; Lack of product approvals means total dependence on future equity dilution to sustain operations.
About LENZ Therapeutics, Inc.
LENZ Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for severe pain and addiction using proprietary small molecule technologies. The company operates in the high-growth neuroscience sector, targeting conditions like chronic non-cancer pain and opioid use disorder with its lead candidate LNT-159.
Analysis
Management Discussion
LENZ reported a net loss of $49.8M for the latest year, reflecting continued heavy investment in its clinical pipeline despite generating no revenue. Cash reserves decreased by $14.9M to $20.3M, while financing activities provided $199.0M, largely through equity issuance to fund operations and markable security purchases.
Industry Overview
The neuroscience and biopharmaceutical industry is characterized by high failure rates in clinical trials but offers massive rewards for successful approvals in pain management. Companies like LENZ compete with large pharmaceutical giants and other specialized biotechs targeting opioid use disorder and chronic pain.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $105.6M | $135.2M | $58.6M |
| Operating Income | $-105.6M | $-135.2M | $-58.6M |
| R&D | $72.8M | $32.1M | $29.8M |
| G&A | $32.9M | $41.0M | $28.8M |
| Stock-Based Comp | $13.5M | $10.6M | $6.4M |
| D&A | $2.4M | $2.4M | $58.0K |
| Depreciation | — | $2.4M | — |
| Other OpEx | $0 | $62.1M | $0 |
| Non-Operating Income | $0 | $0 | $8.8M |
| Interest Income | — | — | $8.6M |
| Pre-Tax Income | $-105.6M | $-135.2M | $-49.8M |
| Income Tax | $0 | $-10.5M | $1.0K |
| Continuing Ops | $-105.6M | $-124.7M | $-49.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-101.1M | $-124.7M | $-49.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-101.1M | $-124.7M | $-49.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $275.4M | $188.0M | $211.9M |
| Cash & Equivalents | $47.7M | $184.3M | $20.2M |
| Prepaid Expenses | $7.1M | $2.2M | $2.8M |
| Other Current Assets | $220.5M | $1.6M | $189.0M |
| Long-Term Assets | $46.5M | $435.0K | $3.4M |
| PP&E (Net) | $22.6M | $0 | $651.0K |
| Operating Leases | $5.6M | $321.0K | $1.3M |
| Other LT Assets | $18.3M | $114.0K | $1.4M |
| Total Assets | $321.9M | $188.5M | $215.3M |
| Current Liabilities | $13.0M | $4.8M | $10.4M |
| Accounts Payable | $2.6M | $250.0K | $4.3M |
| Current Leases | $4.0M | $285.0K | $567.0K |
| Other Current Liab | $6.4M | $4.3M | $-567.0K |
| Long-Term Liabilities | $12.6M | $77.0K | $814.0K |
| LT Operating Leases | $1.7M | $77.0K | $814.0K |
| Other LT Liab | $10.8M | $0 | $0 |
| Total Liabilities | $25.6M | $4.9M | $11.2M |
| Shareholders' Equity | $296.3M | $183.6M | $204.1M |
| Paid-In Capital | $539.7M | $550.6M | $348.9M |
| Retained Earnings | $-242.4M | $-367.1M | $-145.0M |
| AOCI | $-1.0M | $0 | $196.0K |
| Total L&E | $321.9M | $188.5M | $215.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-101.1M | $-124.7M | $-49.8M |
| Non-Cash Adjustments | $14.0M | $86.3M | $765.0K |
| Working Capital Changes | $-967.0K | $-51.7M | $-10.4M |
| Cash from Operations | $-88.0M | $-90.0M | $-59.4M |
| Capital Expenditures | $6.6M | $10.9M | $468.0K |
| Cash from Investing | $-241.9M | $226.3M | $-154.5M |
| Cash from Financing | $597.0K | $190.0K | $199.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-329.2M | $136.5M | $-14.9M |
| Beginning Cash | $378.7M | $49.4M | $35.1M |
| Ending Cash | $49.4M | $186.0M | $20.3M |
Frequently Asked Questions
How does LENZ Therapeutics, Inc. make money?
The company's primary activity is research and development of novel therapeutics, evidenced by significant R&D expenditures of $29.8M. Secondary segments include strategic collaborations and licensing agreements that generated substantial cash flow from financing activities of $199.0M, primarily through common share issuances.
What are the main risks for LENZ?
Complete reliance on future success of clinical trials given current lack of revenue streams; High dilution risk from common share issuances totaling $79.5M during the reporting period; Potential for significant losses to continue as R&D costs remain elevated at $28.8M in G&A plus $29.8M in R&D.
What is LENZ's competitive advantage?
Proprietary small molecule platform enabling unique drug discovery pipelines; Strong balance sheet with $20.3M in cash providing runway for clinical trials; Targeting high-value unmet needs in severe pain and addiction with differentiated mechanisms of action.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.